Stock data
Adial Pharmaceuticals, Inc (ADIL)
Adial Pharmaceuticals, Inc (ADIL) reported net income of -US$7.98M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$7.80M | -US$7.98M | — |
| 2024 | — | — | -US$8.28M | -US$13.20M | — |
| 2023 | — | — | -US$6.89M | -US$5.12M | — |
| 2022 | — | — | -US$10.86M | -US$12.73M | — |
| 2021 | — | — | -US$19.29M | -US$19.42M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$51.99M | — |
| 2026-03-31 | — | -US$2.02M | — |
| 2025-12-31 | — | -US$2.00M | — |
| 2025-09-30 | — | -US$1.79M | — |
| 2025-06-30 | — | -US$1.96M | — |
| 2025-03-31 | — | -US$2.23M | — |
| 2024-12-31 | — | -US$2.07M | — |
| 2024-09-30 | — | -US$2.19M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.